img

euroPCR 2013 .

The most relevant articles and presentations, daily report from the euroPCR 2013 - May, 21 to 24.

If you cannot view the articles, click here

SCAAR: Heparin versus bivalirudin in patients with myocardial infarction without ST segment elevation.
We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who had not received IIBIIIB glycoprotein inhibitors and divided them into two groups: ...

SOURCE XT: Results of the latest generation of the Edwards valve
The first generation of the Edwards valve was stainless steel and bovine pericardium with a profile of 22 to 24 Fr for transfemoral access and up to 33 Fr to apical access . From 2010 it became ...

EnligHTN: treatment of refractory hypertension by catheterization
Lowering blood pressure with renal denervation has been demonstrated in previous studies but unfortunately there was not much data regarding the reduction of clinical events. This study will ...

BIOFLOW II. Stent eluidor de sirolimus com polímero degradável.
This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary ...

SYNTAX II: multiple vessels using iFR / FFR and IVUS
This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable ...

EUROMAX: Bivalirudin during transport to primary angioplasty
The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained ...

DESolveNx trial: Results of the new bioabsorbable platform
This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a ...

REPRISE II: results obtained with the new valve according to VARC criteria
The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received ...

BuMA stent: new sirolimus-eluting stent with bio-degradable polymer
Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used in more than 50,000 patients, is a sirolimus-eluting device with a ...

EXPAND: expanding the applications of bioresorbable platforms
There is little information about the use of bioresorbable vascular devices in patients with a reference diameter ≥4mm, long, bifurcation, calcified or unstable lesions. The BVS-Expand registry ...

PROTAVI-C: Embolic protection during TAVI
Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present a high surgical risk. Some studies have shown that the stroke rate may be higher ...

JUPITER: transapical TAVI device
We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access . Survival at thirty days was 85.1% with a ...

DISCOVER: new low profile valve with little post-implant regurgitation
The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis and high surgical risk. The device is designed to ...

DEFLECT I: cerebral protection device in TAVI
Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device is a nitinol filter covering the origin of the vessels of the ...

HATTRICK-OCT: biodegradable polymer struts coverage versus permanent
Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a ...

DIRECT: results of drug-eluting stent-on-a-wire after 6 months
This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is made of cobalt chrome and the polymer is bio-degradable. 30 patients were included prospectively and ...

POLAR ACS: bio-absorbable platform in acute coronary syndromes
Bio-absorbable devices are considered safe and effective for stable patients but there is still little information regarding their use in acute patients. ACS POLAR Register (POLishAbsorb Registry ...

PRAGUE 19: bioabsorbable platform for patients with ST segment elevation
Absorbable bioplatforms are considered safe and effective in stable patients but their use in the context of acute myocardial infarction with ST segment elevation has not been reported. Low risk of ...

PROMUS PREMIER: new everolimus-eluting stent
The study aims to evaluate clinical, angiographic and IVUS results of the new platinum chromium everolimus stent. The new design of the device has additional proximal connectors to enhance the ...

CENTURY: new clinical results of sirolimus-eluting degradable polymer stent
This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 µm) with a rapid resorption polymer (3 months). Theoretically, it presents less risk of inflammation of the vessel ...

BIOSS: results of the new drug-eluting stent for bifurcations
This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer. It has two separate parts: a larger diameter proximal part and a smaller diameter ...

DEMONSTR8: better endothelial coverage by OCT for the new DES
There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients ...

PATA – STEMI: thromboaspiration correlates with a lower index of microcirculatory resistance
Routine manual vacuum in patients with acute coronary syndrome and ST-segment elevation improves myocardial perfusion according to non-invasive parameters. Invasive assessment of ...

Coherex Wave Crest: New device for atrial appendage closure
Appendage closure devices have emerged as an alternative to anticoagulation in fibrillated patients with a contraindication for it. The study included 63 patients with paroxysmal, persistent or ...

RIPCORD study: FFR changes clinical consideration of chest pain
The objective of this study was to evaluate whether routine use of FFR in all the coronary arteries could change the strategy in stable patients that underwent angiography for the investigation ...

Clinical results of TAVI in Asia
Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with ...

Coronary obstruction registry after TAVI
There is little information in the literature about the obstruction of the coronary ostia after percutaneous aortic valve implantation . 81 TAVI sites and programs and 6688 patients in total ...

IN-PACT CORO: OCT validation of drug-eluting balloons
Drug-eluting balloons could reduce intimal hyperplasia detected by OCT in intmerventions with conventional stents . 30 patients were randomized into 3 groups: 10 patients received conventional ...

RENAL DES: reduction of restenosis in patients with kidney failure
Coronary angioplasty in patients with kidney failure is associated with an increased occurrence of events. This study compared the efficacy of preventing clinical restenosis using an ...

ADVISE II: functional assessment of coronary lesions without adenosine
The pressure ratio in the resting phase of the cardiac cycle is a newly Introduced procedure for the assessment of coronary stenoses based on pressure measurement without adenosine. It generated ...

ELISA 3: Early vs. late invasive strategy in patients without high-risk ST elevation
The invasive strategy is preferred to treat patients with acute coronary syndromes without ST-segment elevation, but the ideal time for the procedure is controversial. This study randomized 542 ...

Treatment of in-stent restenosis with drug-eluting balloon
ISAR-DESIRE 3 did not show that paclitaxel-eluting balloon may be useful for treating restenosis of a sirolimus - eluting stent. This study tests the safety and efficacy of a ...

Pre-dilation of side branch during percutaneous treatment of bifurcation lesions
The simple strategy with a provisional stent is now favored to treat bifurcation lesions ; however, stent implantation in the main branch can compromise or even occlude the side branch. ...

ORBIT II: new atherectomy device
The objective of the study was to test the use of a new atherectomy device to prepare severely calcified lesions. It was an observational, prospective, multicenter study that included 443 patients ...

J- REVERSE: sirolimus-eluting vs. everolimus-eluting stent in bifurcation lesions
Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis . The study was divided into two parts: the first one aimed at comparing, in the ...

Mitral valve repair: were we are and what we would expect for LATAM in the near future
Magnus Seergren 2013-08-21 ...

Value of New Devices for Improving Outcomes
Eberhard Grube 2013-05-21 ...

Why we should close patent foramen ovale (PFO)
Ralph Stephan von Bardeleben 2013-05-21 ...

TAVI: case complication
Marco Perin 2013-05-21 ...

How to prevent TAVI complications with current technology
Antonio Dager 2013-05-21 ...

Top